Meta-Analysis: Do GLP-1 Drugs Improve Heart Risk Factors in Type 1 Diabetes Too?
A systematic review and meta-analysis of RCTs evaluates GLP-1 receptor agonists as adjunctive therapy for cardiometabolic risk factors in type 1 diabetes, extending research beyond their established type 2 diabetes benefits.
Quick Facts
What This Study Found
The meta-analysis evaluated GLP-1RA adjunctive therapy effects on cardiometabolic risk factors in T1DM across available RCTs, extending evidence beyond the established T2DM indications.
Key Numbers
How They Did This
Systematic review and meta-analysis of RCTs from PubMed, Embase, Cochrane Library, and Web of Science through August 2025; PRISMA methodology.
Why This Research Matters
Type 1 diabetes patients also face elevated cardiovascular risk. If GLP-1 drugs provide cardiometabolic benefits in T1DM, millions of additional patients could benefit.
The Bigger Picture
This explores whether GLP-1 drugs' benefits extend across diabetes types — which could fundamentally change type 1 diabetes management from pure glucose control to comprehensive cardiometabolic risk reduction.
What This Study Doesn't Tell Us
Likely few available RCTs in T1DM; studies may be small and heterogeneous; GLP-1 drugs are not approved for T1DM; hypoglycemia risk with insulin combination.
Questions This Raises
- ?Should GLP-1 drugs be considered for overweight type 1 diabetes patients specifically?
- ?Do cardiometabolic benefits in T1DM translate to reduced cardiovascular events long-term?
Trust & Context
- Key Stat:
- T1DM cardiometabolic effects assessed First comprehensive meta-analysis of GLP-1 RA benefits in type 1 diabetes
- Evidence Grade:
- Systematic review and meta-analysis of RCTs — highest evidence synthesis, though limited by available T1DM trial data.
- Study Age:
- Published in 2026 with evidence through August 2025, providing the most current data on GLP-1 drugs in type 1 diabetes.
- Original Title:
- Effect of Glucagon-Like Peptide-1 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
- Published In:
- Diabetes/metabolism research and reviews, 42(1), e70111 (2026)
- Authors:
- Chen, Yizhu, Tang, Yufei, Yue, Rui, Yang, Bo, Wang, Ai, Long, Yang, Xu, Yong, Gao, Chenlin
- Database ID:
- RPEP-15008
Evidence Hierarchy
Frequently Asked Questions
Can people with type 1 diabetes take GLP-1 drugs?
GLP-1 drugs are not currently approved for type 1 diabetes, but some doctors prescribe them off-label. This meta-analysis examines whether they provide cardiometabolic benefits in T1DM beyond what insulin alone achieves.
How is type 1 diabetes different for heart risk?
T1DM patients face 2-3 times higher cardiovascular risk than the general population, driven by factors beyond blood sugar. If GLP-1 drugs improve weight, blood pressure, and lipids in T1DM, they could help reduce this excess risk.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15008APA
Chen, Yizhu; Tang, Yufei; Yue, Rui; Yang, Bo; Wang, Ai; Long, Yang; Xu, Yong; Gao, Chenlin. (2026). Effect of Glucagon-Like Peptide-1 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.. Diabetes/metabolism research and reviews, 42(1), e70111. https://doi.org/10.1002/dmrr.70111
MLA
Chen, Yizhu, et al. "Effect of Glucagon-Like Peptide-1 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.." Diabetes/metabolism research and reviews, 2026. https://doi.org/10.1002/dmrr.70111
RethinkPeptides
RethinkPeptides Research Database. "Effect of Glucagon-Like Peptide-1 Receptor Agonists on Cardi..." RPEP-15008. Retrieved from https://rethinkpeptides.com/research/chen-2026-effect-of-glucagonlike-peptide1-2
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.